[1]
|
McMurray, J.J., Solomon, S.D., Inzucchi, S.E., et al. (2019) Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. New England Journal of Medicine, 381, 1995-2008. https://doi.org/10.1056/NEJMoa1911303
|
[2]
|
Bhatt, D.L., Verma, S. and Braunwald, E. (2019) The DAPA-HF Trial: A Momentous Victory in the War against Heart Failure. Cell Metabolism, 30, 847-849. https://doi.org/10.1016/j.cmet.2019.10.008
|
[3]
|
Packer, M., Anker, S.D., Butler, J., et al. (2020) Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. New England Journal of Medicine, 383, 1413-1424. https://doi.org/10.1056/NEJMoa2022190
|
[4]
|
Nassif, M.E., Windsor, S.L., Tang, F., et al. (2019) Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction: The DEFINE-HF Trial. Circulation, 140, 1463-1476. https://doi.org/10.1161/CIRCULATIONAHA.119.042929
|
[5]
|
Bhatt, D.L., Szarek, M., Steg, P.G., et al. (2021) Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure. New England Journal of Medicine, 384, 117-128. https://doi.org/10.1056/NEJMoa2030183
|
[6]
|
刘瑶, 金立军. 达格列净在心力衰竭中的应用及作用机制的研究进展[J]. 实用心脑肺血管病杂志, 2021, 29(11): 5-9.
|
[7]
|
Dryer, C., Cotter, E.K. and Flynn, B. (2021) Overview of the 2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure with Reduced Ejection Fraction. Journal of Cardiothoracic and Vascular Anesthesia, 35, 2249-2252. https://doi.org/10.1053/j.jvca.2021.03.041
|
[8]
|
Nicholls, M. (2021) The Year in Cardiovascular Medicine 2020: Coronary Intervention. European Heart Journal, 42, 1822-1823. https://doi.org/10.1093/eurheartj/ehaa1021
|
[9]
|
Bauersachs, J. (2021) Heart Failure Drug Treatment: The Fantastic Four. European Heart Journal, 42, 681-683.
https://doi.org/10.1093/eurheartj/ehaa1012
|
[10]
|
谷庆炜, 李倩. 钠-葡萄糖协同转运蛋白2抑制剂治疗糖尿病肾病的研究进展[J]. 医学综述, 2018, 24(17): 3447-3451.
|
[11]
|
Verma, S., Mazer, C.D., Yan, A.T., et al. (2019) Effect of Empagliflozin on Left Ventricular Mass in Patients with Type 2 Diabetes Mellitus and Coronary Artery Disease: The EMPA-HEART CardioLink-6 Randomized Clinical Trial. Circulation, 140, 1693-1702. https://doi.org/10.1161/CIRCULATIONAHA.119.042375
|
[12]
|
Kusaka, H., Koibuchi, N., Hasegawa, Y., Ogawa, H. and Kim-Mitsuyama, S. (2016) Empagliflozin Lessened Cardiac Injury and Reduced Visceral Adipocyte Hypertrophy in Prediabetic Rats with Metabolic Syndrome. Cardiovascular Diabetology, 15, Article No. 157. https://doi.org/10.1186/s12933-016-0473-7
|
[13]
|
Lee, H.-C., Shiou, Y.-L., Jhuo, S.-J. et al. (2019) The Sodi-um-Glucose Co-Transporter 2 Inhibitor Empagliflozin Attenuates Cardiac Fibrosis and Improves Ventricular Hemody-namics in Hypertensive Heart Failure Rats. Cardiovascular Diabetology, 18, Article No. 45. https://doi.org/10.1186/s12933-019-0849-6
|
[14]
|
Zelniker, T.A., Raz, I., Sabatine, M.S. and Wiviott, S.D. (2020) Response by Zelniker et al to Letter Regarding Article, “Effect of Dapagliflozin on Atrial Fibrillation in Patients with Type 2 Diabetes Mellitus: Insights from the DECLARE-TIMI 58 Trial”. Circulation, 142, e129-e130. https://doi.org/10.1161/CIRCULATIONAHA.120.049841
|
[15]
|
Di Franco, A., Cantini, G., Tani, A., et al. (2017) Sodium-Dependent Glucose Transporters (SGLT) in Human Ischemic Heart: A New Potential Pharmacological Target. International Journal of Cardiology, 243, 86-90.
https://doi.org/10.1016/j.ijcard.2017.05.032
|
[16]
|
Connelly, K.A., Zhang, Y., Desjardins, J.-F., Thai, K. and Gilbert, R.E. (2018) Dual Inhibition of Sodium-Glucose Linked Cotransporters 1 and 2 Exacerbates Cardiac Dysfunction Fol-lowing Experimental Myocardial Infarction. Cardiovascular Diabetology, 17, Article No. 99. https://doi.org/10.1186/s12933-018-0741-9
|
[17]
|
Li, Z., Agrawal, V., Ramratnam, M., et al. (2019) Cardiac Sodi-um-Dependent Glucose Cotransporter 1 Is a Novel Mediator of Ischaemia/Reperfusion Injury. Cardiovascular Research, 115, 1646-1658. https://doi.org/10.1093/cvr/cvz037
|
[18]
|
郑旭辉, 李新立. 钠-葡萄糖协同转运蛋白2抑制剂的研究进展及治疗心力衰竭的机制探讨[J]. 内科理论与实践, 2020, 15(2): 120-123.
|
[19]
|
Peng, X., Li, L., Zhang, M., et al. (2020) Sodium-Glucose Cotransporter 2 Inhibitors Potentially Prevent Atrial Fibrillation by Ameliorating Ion Han-dling and Mitochondrial Dysfunction. Frontiers in Physiology, 11, Article 912.
https://doi.org/10.3389/fphys.2020.00912
|
[20]
|
Dridi, H., Kushnir, A., Zalk, R., et al. (2020) Intracellular Calcium Leak in Heart Failure and Atrial Fibrillation: A Unifying Mechanism and Therapeutic Target. Nature Reviews Cardiology, 17, 732-747.
https://doi.org/10.1038/s41569-020-0394-8
|
[21]
|
Scott Jr., L., Li, N. and Dobrev, D. (2019) Role of Inflammatory Signaling in Atrial Fibrillation. International Journal of Cardiology, 287, 195-200. https://doi.org/10.1016/j.ijcard.2018.10.020
|
[22]
|
Verkhratsky, A., Trebak, M., Perocchi, F., Khananshvili, D. and Sekler, I. (2018) Crosslink between Calcium and Sodium Signalling. Experimental Physiology, 103, 157-169. https://doi.org/10.1113/EP086534
|
[23]
|
Suleiman, M., Abdulrahman, N., Yalcin, H. and Mraiche, F. (2018) The Role of CD44, Hyaluronan and NHE1 in Cardiac Remodeling. Life Sciences, 209, 197-201. https://doi.org/10.1016/j.lfs.2018.08.009
|
[24]
|
Karg, M.V., Bosch, A., Kannenkeril, D., et al. (2018) SGLT-2-Inhibition with Dapagliflozin Reduces Tissue Sodium Content: A Randomised Controlled Trial. Cardiovascular Diabetology, 17, Article No. 5.
https://doi.org/10.1186/s12933-017-0654-z
|
[25]
|
Baartscheer, A., Schumacher, C.A., Wüst, R.C.I., et al. (2017) Empagliflozin Decreases Myocardial Cytoplasmic Na through Inhibition of the Cardiac Na+/H+ Exchanger in Rats and Rabbits. Diabetologia, 60, 568-573.
https://doi.org/10.1007/s00125-016-4134-x
|
[26]
|
Uthman, L., Baartscheer, A., Bleijlevens, B., et al. (2018) Class Effects of SGLT2 Inhibitors in Mouse Cardiomyocytes and Hearts: Inhibition of Na+/H+ Exchanger, Lowering of Cyto-solic Na+ and Vasodilation. Diabetologia, 61, 722-726.
https://doi.org/10.1007/s00125-017-4509-7
|
[27]
|
Ye, Y., Jia, X., Bajaj, M. and Birnbaum, Y. (2018) Dapagliflozin Attenuates Na+/H+ Exchanger-1 in Cardiofibroblasts via AMPK Activation. Cardiovascular Drugs and Therapy, 32, 553-558. https://doi.org/10.1007/s10557-018-6837-3
|
[28]
|
Mudaliar, A., Alloju, S. and Henry, R.R. (2016) Can a Shift in Fuel Energetics Explain the Beneficial Cardiorenal Outcomes in the EMPA-REG OUTCOME Study? A Unify-ing Hypothesis. Diabetes Care, 39, 1115-1122.
https://doi.org/10.2337/dc16-0542
|
[29]
|
Santos-Gallego, C.G., Requena-Ibanez, J.A., San Antonio, R., et al. (2019) Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energetics. Journal of the American College of Cardiology, 73, 1931-1944. https://doi.org/10.1016/j.jacc.2019.01.056
|
[30]
|
Nielsen, R., Møller, N., Gormsen, L.C., et al. (2019) Cardiovascu-lar Effects of Treatment with the Ketone Body 3-Hydroxybutyrate in Chronic Heart Failure Patients. Circulation, 139, 2129-2141.
https://doi.org/10.1161/CIRCULATIONAHA.118.036459
|
[31]
|
Guyenet, P.G. (2017) Putative Mechanism of Salt-Dependent Neurogenic Hypertension: Cell-Autonomous Activation of Organum Vasculosum Laminae Terminalis Neurons by Hypernatremia. Hypertension, 69, 20-22.
https://doi.org/10.1161/HYPERTENSIONAHA.116.08470
|
[32]
|
Kang, S., Verma, S., Fatehi Hassanabad, A., et al. (2020) Direct Effects of Empagliflozin on Extracellular Matrix Remodelling in Human Cardiac Myofibroblasts: Novel Translational Clues to Explain EMPA-REG OUTCOME Results. The Canadian Journal of Cardiology, 36, 543-553. https://doi.org/10.1016/j.cjca.2019.08.033
|
[33]
|
Leng, W., Ouyang, X., Lei, X., et al. (2016) The SGLT-2 Inhibitor Dapagliflozin Has a Therapeutic Effect on Atherosclerosis in Diabetic ApoE−/− Mice. Mediators of Inflammation, 2016, Article ID: 6305735.
https://doi.org/10.1155/2016/6305735
|
[34]
|
Thorp, A.A. and Schlaich, M.P. (2015) Relevance of Sympathetic Nervous System Activation in Obesity and Metabolic Syndrome. Journal of Diabetes Research, 2015, Article ID: 341583. https://doi.org/10.1155/2015/341583
|
[35]
|
胡鑫渝, 周音频, 凌智瑜, 肖鹏. 钠-葡萄糖共转运蛋白2抑制剂治疗心力衰竭的临床研究进展[J]. 重庆医学, 2021, 50(19): 3375-3379.
|
[36]
|
Mori, H., Okada, Y., Kawaguchi, M. and Tanaka, Y. (2016) A Case of Type 2 Diabetes with a Change from a Non-Dipper to a Dipper Blood Pressure Pattern by Dapagliflozin. Journal of UOEH, 38, 149-153.
https://doi.org/10.7888/juoeh.38.149
|
[37]
|
Chilton, R., Tikkanen, I., Hehnke, U., Woerle, H.J .and Johansen, O.E. (2017) Impact of Empagliflozin on Blood Pressure in Dipper and Non-Dipper Patients with Type 2 Diabetes Mellitus and Hypertension. Diabetes, Obesity & Metabolism, 19, 1620-1624. https://doi.org/10.1111/dom.12962
|
[38]
|
李毅, 曹杨. 钠-葡萄糖协同转运蛋白2抑制剂: 心力衰竭治疗领域的“跨界明星” [J]. 中国现代医学杂志, 2021, 31(10): 1-3.
|
[39]
|
Nugent, M.A. and Iozzo, R.V. (2000) Fibroblast Growth Factor-2. The International Journal of Biochemistry & Cell Biology, 32, 115-120. https://doi.org/10.1016/S1357-2725(99)00123-5
|
[40]
|
马乐乐, 赵飞. bFGF、HGF与风湿性心脏病心房颤动患者心房纤维化的关系[J]. 中国临床研究, 2016, 29(10): 1323-1326.
|
[41]
|
隗祎, 任学军. 心房颤动心房纤维化相关生物标志物研究进展[J]. 心肺血管病杂志, 2019, 38(3): 313-316.
|
[42]
|
Li, Y., Jian, Z., Yang, Z.Y., et al. (2013) Increased Expression of Connective Tissue Growth Factor and Transforming Growth Fac-tor-Beta-1 in Atrial Myocardium of Patients with Chronic Atrial Fibrillation. Cardiology, 124, 233-240.
https://doi.org/10.1159/000347126
|
[43]
|
Ko, W.-C., Hong, C.-Y., Hou, S.-M., et al. (2011) Elevated Expression of Connective Tissue Growth Factor in Human Atrial Fibrillation and Angiotensin II-Treated Cardiomyocytes. Circulation Journal, 75, 1592-1600.
https://doi.org/10.1253/circj.CJ-10-0892
|
[44]
|
Kim, K.-H., Park, G.-T., Kim, Y.-B., et al. (2004) Expression of Connective Tissue Growth Factor, a Biomarker in Senescence of Human Diploid Fibroblasts, Is up-Regulated by a Transforming Growth Factor-β-Mediated Signaling Pathway. Biochemical and Biophysical Research Communications, 318, 819-825.
https://doi.org/10.1016/j.bbrc.2004.04.108
|
[45]
|
Kiryu, M., Niwano, S., Niwano, H., et al. (2012) Angiotensin II-Mediated up-Regulation of Connective Tissue Growth Factor Promotes Atrial Tissue Fibrosis in the Canine Atrial Fi-brillation Model. EP Europace, 14, 1206-1214.
https://doi.org/10.1093/europace/eus052
|
[46]
|
陈铭, 朱莉, 刘玲, 等. 心房颤动患者血清中CTGF、bFGF、HGF和TGF-β1/Smads信号通路的表达及意义[J]. 中国实验诊断学, 2021, 25(2): 256-258.
|
[47]
|
Park, S.-J., On, Y.K., Kim, J.S., et al. (2013) Transforming Growth Factor β1-Mediated Atrial Fibrotic Activity and the Recovery of Atrial Mechanical Contraction after Surgical Maze Procedure. International Journal of Cardiology, 164, 232-237. https://doi.org/10.1016/j.ijcard.2013.01.066
|
[48]
|
梁宇明, 何燕. TGF-β/smads信号通路对心肌纤维化心房颤动作用及机制的研究进展[J]. 山东医药, 2018, 58(33): 97-99.
|
[49]
|
Taniyama, Y., Morishita, R., Nakagami, H., et al. (2000) Potential Contribution of a Novel Antifibrotic Factor, Hepatocyte Growth Factor, to Prevention of Myocardial Fi-brosis by Angiotensin II Blockade in Cardiomyopathic Hamsters. Circulation, 102, 246-252. https://doi.org/10.1161/01.CIR.102.2.246
|
[50]
|
Mungunsukh, O., McCart, E.A. and Day, R.M. (2014) Hepatocyte Growth Factor Isoforms in Tissue Repair, Cancer, and Fibrotic Remodeling. Biomedicines, 2, 301-326. https://doi.org/10.3390/biomedicines2040301
|
[51]
|
易欣, 黎明江, 马乐乐, 等. 结缔组织生长因子、肝细胞生长因子与风湿性心脏病心房颤动患者心房纤维化的关系[J]. 武汉大学学报(医学版), 2012, 33(6): 824-828.
|
[52]
|
Mazer, C.D., Hare, G.M., Connelly, P.W., et al. (2020) Effect of Empagliflozin on Erythropoietin Levels, Iron Stores, and Red Blood Cell Morphology in Patients with Type 2 Diabetes Mellitus and Coronary Artery Disease. Circulation, 141, 704-707. https://doi.org/10.1161/CIRCULATIONAHA.119.044235
|
[53]
|
Sano, M., Takei, M., Shiraishi, Y. and Suzuki, Y. (2016) Increased Hematocrit during Sodium-Glucose Cotransporter 2 Inhibitor Therapy In-dicates Recovery of Tubulointerstitial Function in Diabetic Kidneys. Journal of Clinical Medicine Research, 8, 844-847. https://doi.org/10.14740/jocmr2760w
|
[54]
|
Zou, C.-Y., Liu, X.-K., Sang, Y.-Q., et al. (2019) Effects of SGLT2 In-hibitors on Cardiovascular Outcomes and Mortality in Type 2 Diabetes: A Meta-Analysis. Medicine, 98, e18245. https://doi.org/10.1097/MD.0000000000018245
|
[55]
|
Meagher, P., Adam, M., Civitarese, R., Bugyei-Twum, A. and Connelly, K.A. (2018) Heart Failure with Preserved Ejection Fraction in Diabetes: Mechanisms and Management. The Canadian Journal of Cardiology, 34, 632-643.
https://doi.org/10.1016/j.cjca.2018.02.026
|
[56]
|
Al-Awar, A., Kupai, K., Veszelka, M., et al. (2016) Experimental Diabetes Mellitus in Different Animal Models. Journal of Diabetes Research, 2016, Article ID: 9051426. https://doi.org/10.1155/2016/9051426
|
[57]
|
Sato, T., Aizawa, Y., Yuasa, S., et al. (2018) The Effect of Dapagli-flozin Treatment on Epicardial Adipose Tissue Volume. Cardiovascular Diabetology, 17, Article No. 6. https://doi.org/10.1186/s12933-017-0658-8
|
[58]
|
Kim, J.A., Wei, Y. and Sowers, J.R. (2008) Role of Mitochondri-al Dysfunction in Insulin Resistance. Circulation Research, 102, 401-414. https://doi.org/10.1161/CIRCRESAHA.107.165472
|
[59]
|
Yurista, S.R., Silljé, H.H.W., Oberdorf-Maass, S.U., et al. (2019) Sodium-Glucose Co-Transporter 2 Inhibition with Empagliflozin Improves Cardiac Function in Non-Diabetic Rats with Left Ventricular Dysfunction after Myocardial Infarction. European Journal of Heart Failure, 21, 862-873. https://doi.org/10.1002/ejhf.1473
|
[60]
|
Durak, A., Olgar, Y., Degirmenci, S., et al. (2018) A SGLT2 Inhibitor Dapagliflozin Suppresses Prolonged Ventricular-Repolarization through Augmentation of Mitochondrial Function in In-sulin-Resistant Metabolic Syndrome Rats. Cardiovascular Diabetology, 17, Article No. 144. https://doi.org/10.1186/s12933-018-0790-0
|
[61]
|
Lega, I.C, Bronskill, S.E, Campitelli, M.A, et al. (2019) Sodium Glucose Cotransporter 2 Inhibitors and Risk of Genital Mycotic and Urinary Tract Infection: A Population-Based Study of Older Women and Men with Diabetes. Diabetes, Obesity and Metabolism, 21, 2394-2404. https://doi.org/10.1111/dom.13820
|
[62]
|
Wang, L., Voss, E.A, Weaver, J., et al. (2019) Diabetic Ketoacidosis in Patients with Type 2 Diabetes Treated with Sodium Glucose Co-Transporter 2 Inhibitors versus Other Antihyperglyce-mic Agents: An Observational Study of Four US Administrative Claims Databases. Pharmacoepidemiology and Drug Safety, 28, 1620-1628.
https://doi.org/10.1002/pds.4887
|
[63]
|
Iqbal, I., Hamid, M., Khan, M.A.A., Kainat, A. and Tariq, S. (2019) Dapagliflozin-Induced Late-Onset Euglycemic Diabetic Ketoacidosis. Cureus, 11, e6089. https://doi.org/10.7759/cureus.6089
|
[64]
|
Park, J.H., Seo, I., Shim, H.M. and Cho, H. (2020) Melatonin Amelio-rates SGLT2 Inhibitor-Induced Diabetic Ketoacidosis by Inhibiting Lipolysis and Hepatic Ketogenesis in Type 2 Diabetic Mice. Journal of Pineal Research, 68, e12623. https://doi.org/10.1111/jpi.12623
|
[65]
|
Lou, Y., Yu, Y., Duan, J., et al. (2020) Sodium-Glucose Cotransporter 2 Inhibitors and Fracture Risk in Patients with Type 2 Diabetes Mellitus: A Meta-Analysis of Randomized Controlled Trials. Therapeutic Advances in Chronic Disease, 11, Article ID: 1754253375. https://doi.org/10.1177/2040622320961599
|
[66]
|
Li, X., Li, T., Cheng, Y., et al. (2019) Effects of SGLT2 Inhibi-tors on Fractures and Bone Mineral Density in Type 2 Diabetes: An Updated Meta-Analysis. Diabetes/Metabolism Re-search and Reviews, 35, e3170.
https://doi.org/10.1002/dmrr.3170
|